Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) EPS (Weighted Average and Diluted) (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.21 as the latest value for Q4 2024.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 36.36% to -$0.21 in Q4 2024 year-over-year; TTM through Dec 2024 was -$1.27, a 30.6% increase, with the full-year FY2024 number at -$1.27, up 30.6% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.21 for Q4 2024 at Actinium Pharmaceuticals, up from -$0.37 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.21 in Q4 2024 to a low of -$0.58 in Q2 2023.
  • A 4-year average of -$0.36 and a median of -$0.36 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 84.39% in 2023, then soared 36.36% in 2024.
  • Actinium Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.39 in 2021, then fell by 20.1% to -$0.47 in 2022, then rose by 29.44% to -$0.33 in 2023, then skyrocketed by 36.36% to -$0.21 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's EPS (Weighted Average and Diluted) are -$0.21 (Q4 2024), -$0.37 (Q3 2024), and -$0.38 (Q2 2024).